Chronic Obstructive Pulmonary Disease News and Research RSS Feed - Chronic Obstructive Pulmonary Disease News and Research

The World Health Organisation (WHO) has described Chronic Obstructive Pulmonary Disorder (COPD) as a global epidemic; an estimated 210 million people have COPD worldwide and more than 3 million people died of the condition in 2005, which is equal to 5% of all deaths globally that year. Total deaths from COPD are projected to increase by more than 30% in the next 10 years without interventions to cut risks, particularly exposure to tobacco smoke.
New national survey finds lack of COPD knowledge among patients

New national survey finds lack of COPD knowledge among patients

In a new national survey of chronic obstructive pulmonary disease (COPD) patients, Health Union reveals a surprising lack of awareness of risk factors and knowledge of diagnosis stage among patients. Results demonstrate a severe impact on quality of life, employment, and ability to afford treatment. [More]
Researchers uncover groundbreaking evidence for developing vaccine to prevent middle ear infections

Researchers uncover groundbreaking evidence for developing vaccine to prevent middle ear infections

Researchers from Griffith University's Institute for Glycomics, together with the Nationwide Children's Hospital in Ohio, have uncovered groundbreaking evidence to help vaccine developers prevent middle ear infections. [More]
Factors linked with increased risk of falling identified in patients with COPD

Factors linked with increased risk of falling identified in patients with COPD

In a recent year-long study, 40% of patients with chronic obstructive pulmonary disease (COPD) experienced falls, with more than 75% of these falling multiple times. [More]
COPD risk may occur during childhood and adolescence

COPD risk may occur during childhood and adolescence

Chronic obstructive pulmonary disease (COPD) is one of most common causes of death in the world today - active smoking accounting for approx. 85% of all cases. Yet ground-breaking research from the University of Copenhagen indicates that accelerated decline of lung function is not a prerequisite for COPD. [More]
Evidence-based initiative aims to prevent avoidable hospital readmissions

Evidence-based initiative aims to prevent avoidable hospital readmissions

A statewide effort led by key stakeholders in South Carolina successfully organized and implemented an evidence-based initiative aimed at improving the quality of healthcare transitions after hospital discharge to prevent avoidable readmissions. [More]
New portable system can produce life-saving NO from air by means of electrical spark

New portable system can produce life-saving NO from air by means of electrical spark

Treatment with inhaled nitric oxide (NO) has proven to be life saving in newborns, children and adults with several dangerous conditions, but the availability of the treatment has been limited by the size, weight and complexity of equipment needed to administer the gas and the therapy's high price. [More]
Boehringer Ingelheim’s Spiolto Respimat approved for COPD treatment in first European countries

Boehringer Ingelheim’s Spiolto Respimat approved for COPD treatment in first European countries

Boehringer Ingelheim today announced regulatory authority approvals for Spiolto Respimat (tiotropium/olodaterol) in first European countries. Spiolto Respimat is a once-daily maintenance treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD). [More]
STIOLTO RESPIMAT Inhalation Spray now available for treatment of COPD across the U.S.

STIOLTO RESPIMAT Inhalation Spray now available for treatment of COPD across the U.S.

Boehringer Ingelheim Pharmaceuticals, Inc. announced today that STIOLTO RESPIMAT (tiotropium bromide and olodaterol) Inhalation Spray is now available by prescription at pharmacies across the United States. [More]
Long-term smokers and ex-smokers have respiratory-related impairments

Long-term smokers and ex-smokers have respiratory-related impairments

More than half of long-term smokers and ex-smokers who are considered disease-free because they passed lung-function tests have respiratory-related impairments when more closely evaluated with lung imaging, walking and quality-of-life tests. Many of those people likely have the earliest stages of chronic obstructive pulmonary disease, an incurable progressive disease (COPD) that is the third leading cause of death in the United States. [More]

Helmholtz Zentrum München scientists investigating molecular causes of COPD

At present, there is a lack of effective treatments that target the causes of chronic obstructive pulmonary disease (COPD). Scientists of the Comprehensive Pneumology Center at Helmholtz Zentrum München are therefore investigating the molecular causes of COPD in order to intervene specifically. [More]
Pulmatrix announces new inhaled anti-infective therapy to treat CF-associated fungal infections

Pulmatrix announces new inhaled anti-infective therapy to treat CF-associated fungal infections

Pulmatrix, Inc., a clinical stage biopharmaceutical company developing innovative inhaled therapies for serious pulmonary diseases, today announced a new drug candidate, PUR1900, an inhaled anti-infective to treat fungal infections associated with cystic fibrosis (CF). [More]
Pulmatrix completes previously announced merger and closes $10 million in private placement

Pulmatrix completes previously announced merger and closes $10 million in private placement

Pulmatrix, Inc., previously known as Ruthigen, Inc., today announced the completion of its previously announced merger, effective June 15, 2015, and the closing of a private placement generating aggregate gross proceeds of $10.0 million. Participants in the private placement included pre-merger investors in Pulmatrix such as funds affiliated with 5AM Ventures, ARCH Venture Partners and Polaris Partners, as well as funds affiliated with Altitude Life Science Ventures. [More]
Pulmatrix signs ex-U.S. development agreement with Mylan for bronchodilator therapy

Pulmatrix signs ex-U.S. development agreement with Mylan for bronchodilator therapy

Pulmatrix, a clinical stage biopharmaceutical company developing innovative inhaled therapies for serious pulmonary diseases, today announced that it has entered into an ex-U.S. development agreement with Mylan N.V., one of the world's leading global pharmaceutical companies. [More]
Lung cancer patients with comorbid conditions face higher risk of death

Lung cancer patients with comorbid conditions face higher risk of death

Lung cancer patients with comorbid conditions such as chronic obstructive pulmonary disease, diabetes, or congestive heart failure had a higher risk of death than lung cancer patients without comorbid conditions, according to a study published in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research. [More]
Switching from Remicade to Inflectra benefits patients with rheumatic diseases

Switching from Remicade to Inflectra benefits patients with rheumatic diseases

Hospira, Inc., a global leader in biosimilars, today announced the results of an independent clinical study, showing patients with rheumatic diseases experienced comparable clinical effectiveness and safety after switching from Remicade™ to Inflectra. [More]
People across the world are living longer but spending more time in ill health

People across the world are living longer but spending more time in ill health

People across the world are living longer but spending more time in ill health as rates of nonfatal diseases and injuries - including diabetes and hearing loss - decline more slowly than death rates, according to a new analysis of 301 diseases and injuries in 188 countries. [More]
GBD analysis shows over 95% of global population has health problems

GBD analysis shows over 95% of global population has health problems

Just one in 20 people worldwide (4·3%) had no health problems in 2013, with a third of the world's population (2·3 billion individuals) experiencing more than five ailments, according to a major new analysis from the Global Burden of Disease Study (GBD) 2013, published in The Lancet. [More]
Transitional and progressive care can help patients achieve functional recovery faster in post-acute care

Transitional and progressive care can help patients achieve functional recovery faster in post-acute care

Transitional care has emerged as a way to reduce hospital readmissions, and progressive care nurses can play an integral role in efforts to help patients achieve functional recovery faster in post-acute care, according to an article in the June issue of Critical Care Nurse. [More]

Airway granulocytes potential CF biomarker for fungal lung disease

Researchers have found that accumulation in the airways of CXCR4+ granulocytes is associated with chronic colonisation by the fungus Aspergillus fumigatus. [More]
Pulmonary rehabilitation ‘should include sleep assessment’

Pulmonary rehabilitation ‘should include sleep assessment’

Researchers say that pulmonary rehabilitation programmes for patients with moderate to severe chronic obstructive pulmonary disease should include sleep assessment. [More]
Advertisement